A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Clinical Trials Information Group Officer
- Telefonnummer: 86-0311-69085587
- E-mail: ctr-contact@cspc.cn
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:
- HER2-negative confirmed by histological or cytological testing;
- Pathological report is available to confirm HR status.
- 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
- 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
- 5. Has adequate organ and system functions within 7 days prior to the first dose.
- 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
- 7. Expected survival ≥ 3 months.
Exclusion Criteria:
- 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
- 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
- 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
- 4. With a history of other primary malignant tumors within 5 years before administration.
- 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
- 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
- 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
- 8. Current clinically significant abnormal interstitial lung disease.
- 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
- 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
- 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
- 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
- 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
- 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
- 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
- 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
- 17. Concurrent participation in another interventional clinical study.
- 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HB1801
|
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
|
|
Eksperimentel: Docetaxel (Taxotere®)
|
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS)
Tidsramme: up to approximately 2 years after the first enrollment
|
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
|
up to approximately 2 years after the first enrollment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) assessed per RECIST v1.1
Tidsramme: up to approximately 2 years after the first enrollment
|
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
|
up to approximately 2 years after the first enrollment
|
|
Duration of Response (DOR)
Tidsramme: up to approximately 2 years after the first enrollment
|
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
|
up to approximately 2 years after the first enrollment
|
|
Disease Control Rate (DCR)
Tidsramme: up to approximately 2 years after the first enrollment
|
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
|
up to approximately 2 years after the first enrollment
|
|
Overall Survival (OS)
Tidsramme: up to approximately 2 years after the first enrollment
|
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
|
up to approximately 2 years after the first enrollment
|
|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Tidsramme: up to approximately 2 years after the first enrollment
|
up to approximately 2 years after the first enrollment
|
|
|
Plasma concentration of docetaxel (free and total)
Tidsramme: After completion of infusion administration on Day 1 of Cycle 1
|
After completion of infusion administration on Day 1 of Cycle 1
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HB1801-017
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .